BC Extra | Jan 21, 2020
Company News

Horizon gains first FDA approval in thyroid eye disease

With FDA’s approval of Horizon’s thyroid eye disease drug -- the first for the indication -- the company is looking ahead to add to its rare disease pipeline through deal-making. The approval comes ahead of...
BC Extra | Dec 14, 2019
Company News

Dec. 13 Company Quick Takes: Horizon, Intercept, Imfinzi, Evenity and Numab-3SBio

FDA panel backs Horizon's eye disease candidate  FDA’s Dermatologic and Ophthalmic Drugs Advisory Committee voted unanimously Friday that the benefits of teprotumumab to treat active thyroid eye disease outweigh the potential risks. The mAb against...
BC Extra | Nov 23, 2019
Company News

Nov. 22 Company Quick Takes: AZ’s Btk inhibitor gains expanded approval; plus WuXi Vaccines, SK Bio, ViiV, Horizon and Neon

Label expansion for AZ’s Calquence under Project ORBIS  FDA approved an sNDA for Calquence acalabrutinib from AstraZeneca plc (LSE:AZN; NYSE:AZN) to treat chronic lymphocytic leukemia and small lymphocytic leukemia under the agency’s Real-Time Oncology Review...
BC Innovations | Oct 29, 2019
Distillery Therapeutics

Combined inhibition of G12C-mutant KRAS, mTOR and IGF1R for NSCLC

DISEASE CATEGORY: Cancer INDICATION: Non-small cell lung cancer (NSCLC) Triple therapy with KRAS-G12C, mTOR and IGF1R inhibitors could treat KRAS G12C-mutant NSCLC. Whole genome screening of an shRNA library for targets whose inhibition enhanced the...
BC Extra | Sep 9, 2019
Company News

Sept. 9 Company Quick Takes: Alexion licenses Japanese rights to Eidos candidate; plus Molecular Partners-Allergan, Horizon, Alnylam

Alexion gets Japanese rights to BridgeBio's ATTR therapy  The Eidos Therapeutics Inc. (NASDAQ:EIDX) subsidiary of BridgeBio Pharma Inc. (NASDAQ:BBIO) granted Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) exclusive rights to develop and commercialize transthyretin-mediated amyloidosis (ATTR) candidate AG10...
BC Innovations | Aug 29, 2019
Distillery Techniques

STAT3-based gene signature to predict response to glioblastoma targeted therapy

TECHNIQUES CATEGORY: Biomarkers TECHNOLOGY: Gene profiling A STAT3-based gene expression signature could identify glioblastoma multiforme (GBM) patients that will respond to STAT3 inhibitors as monotherapies or in combination with IGF1R (insulin-like growth factor-1 receptor; CD221)...
BC Extra | Jul 11, 2019
Company News

July 10 Company Quick Takes: I-Mab licenses MacroGenics mAb; plus Mirati-Novartis, Jazz-Redx, Sanofi, Horizon and more

I-Mab gains China rights to enoblituzumab I-Mab Biopharma (Shanghai, China) gained exclusive rights to enoblituzumab from MacroGenics Inc. (NASDAQ:MGNX) in China, Hong Kong, Macao and Taiwan for $15 million up front. MacroGenics is eligible for...
BC Week In Review | Apr 12, 2019
Clinical News

Merrimack discontinues last clinical candidate

Merrimack discontinued development of MM-310 -- the company's last remaining product in clinical testing -- after a safety update showed that a Phase I trial in solid tumor patients "would not be able to reach...
BC Extra | Apr 2, 2019
Financial News

Fusion raises $105M series B for radiopharmaceutical pipeline

Aiming to advance its pipeline of targeted α-particle radiopharmaceuticals for cancer, Fusion raised $105 million in an oversubscribed series B round led by Varian and new investor OrbiMed Advisors. Fusion Pharmaceuticals Inc. (Hamilton, Ontario) labels...
BC Extra | Mar 7, 2019
Financial News

Follow-on roundup: Horizon, Apellis, Epizyme

Horizon, Apellis and Epizyme each priced follow-ons raising a total of $552 million. Horizon Pharma plc (NASDAQ:HZNP) raised $300 million late Wednesday through the sale of 12 million shares at $24.50. The price is a...
Items per page:
1 - 10 of 248